Bivalirudin in pediatric patients maintained on extracorporeal life support

Pediatric Critical Care Medicine

Volumn 14, Issue 4, 2013, Pages

  Nagle, Erin L ^a   Dager, William E ^a   Duby, Jeremiah J ^a   Roberts, A Josh ^a   Kenny, Laura E ^a   Murthy, Manasa S ^a   Pretzlaff, Robert K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulation; Bivalirudin; Extracorporeal life support; Extracorporeal membrane oxygenation; Heparin; Pediatric

Indexed keywords

HIRULOG;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; INFANT; MAINTENANCE DRUG DOSE; MALE; NEWBORN; PARTIAL THROMBOPLASTIN TIME; PEDIATRIC ADVANCED LIFE SUPPORT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTITHROMBINS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HIRUDINS; HUMANS; INFANT; INFANT, NEWBORN; LIFE SUPPORT CARE; MALE; PARTIAL THROMBOPLASTIN TIME; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOSIS; TIME FACTORS;

EID: 84877767913     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0b013e31827200b6     Document Type: Article

References (29)

1. Oliver WC: Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009; 13:154-175
2. Edmunds LH Jr, Colman RW: Thrombin during cardiopulmonary bypass. Ann Thorac Surg 2006; 82:2315-2322
3. Warkentin TE, Greinacher A, Koster A, et al; American College of Chest Physicians: Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidencebased clinical practice guidelines (Eighth Edition). Chest 2008; 133(6 Suppl):340S-380S
4. Package Insert. Angiomax. Parsippany, NJ, Medicines Company, Dec. 2000
5. Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203-2216
6. Stone GW, Witzenbichler B, Guagliumi G, et al: HORIZONS-AMI Trial Investigators: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218-2230
7. Kushner FG, Hand M, Smith SC, et al: 2009 ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the ACC/AHA task force on practice guidelines. J Am Coll Cardiol 2009, 54:2205-41
8. Anderson JL, Adams CD, Antman EM, et al: American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Societyof Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007; 50:e1-e157
9. Tsu LV, Dager WE: Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia. Ann Pharmacother 2011; 45:1185-1192
10. Koster A, Dyke CM, Aldea G, et al: Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: Results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83:572-577
11. Dyke CM, Smedira NG, Koster A, et al: A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006; 131:533-539
12. Package Insert. Argatroban. Research Triangle Park, NC, Glaxo Smith Kline, March 2009
13. Package Insert. Refludan. Montville, NJ, Berlex, October 2004
14. Stratmann G, deSilva AM, Tseng EE, et al: Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparininduced thrombocytopenia. Anesth Analg 2004; 98:1635-1639
15. Apostolidou I, Sweeney MF, Missov E, et al: Acute left atrial thrombus after recombinant factor VIIa administration during left ventricular assist device implantation in a patient with heparin-induced thrombocytopenia. Anesth Analg 2008; 106:404-408
16. Nagle EL, Tsu LV, Dager WE: Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Ann Pharmacother 2011; 45:e47
17. Vavra KA, Lutz MF, Smythe MA: Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants. Ann Pharmacother 2010; 44:718-726
18. Dager WE, Dougherty JA, Nguyen PH, et al: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy 2007; 27:564-587
19. Cornell T, Wyrick P, Fleming G, et al: A case series describing the use of argatroban in patients on extracorporeal circulation. ASAIO J 2007; 53:460-463
20. Dager WE, Gosselin RC, Yoshikawa R, Owings JT: Use of lepirudin in continuous extra-corporeal membranous oxygenation. Ann Pharmacother 2004; 38:598-601
21. Koster A, Weng Y, Bottcher W, Gromann T, Kuppe H, Hetzer R: Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg 2007; 83:1865-1867
22. Pappalardo F, Maj G, Scandroglio A, Sampietro F, Zangrillo A, Koster A: Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion 2009; 24:135-137
23. Pollak U, Yacobobich J, Tamary H, et al: Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: A case report and review of the literature. J Extra Corpor Technol 2011; 43:5-12
24. Ranucci M, Ballotta A, Kandil H, et al: Surgical and Clinical Outcome Research Group: Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011; 15:R275
25. Gaffney AM, Wildhirt SM, Griffin MJ, et al: Extracorporeal life support. BMJ 2010; 341:c5317
26. Dager WE, Young N: Reversal of bivalirudin with recombinant activated factor VII during cardiac surgery. Presented at Anticoagulation Forum 2011, Boston, MA. May 2011. J Thromb Thrombolysis 2011; 31:393 (abstract)
27. Haines NM, Rycus PT, Zwischenberger JB, et al: Extracorporeal Life Support Registry Report 2008: Neonatal and pediatric cardiac cases. ASAIO J 2009; 55:111-116
28. Carroll RC, Chavez JJ, Simmons JW, et al: Measurement of patients' bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: A comparison to a standard activated clotting time. Anesth Analg 2006; 102:1316-1319
29. Gosselin RC, King JH, Janatpour KA, et al: Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother 2004; 38:1383-1388